FDA Withholds COVID and Shingles Vaccine Studies, Raising Questions About Transparency

A decision made behind closed doors at the FDA is now fueling a growing national conversation about science, transparency, and public trust in vaccines.

Federal officials recently blocked or withdrew the publication of several taxpayer-funded studies examining the safety of COVID-19 and shingles vaccines. According to reports confirmed by the Department of Health and Human Services, the studies analyzed millions of patient records and found that serious side effects from the vaccines were extremely rare. Despite those findings, the research was pulled back before publication or conference presentation.

The controversy centers on multiple studies conducted by FDA scientists and outside data contractors. Two COVID-19 vaccine studies had reportedly already been accepted by peer-reviewed medical journals before being withdrawn. Additional studies involving the shingles vaccine Shingrix were also halted after agency officials reportedly declined to approve their submission to a major drug safety conference. Critics argue that the move raises concerns about whether scientific findings are being filtered for political or ideological reasons rather than scientific standards.

What the Studies Found — and Why They Were Pulled

The blocked studies focused on large-scale vaccine safety monitoring programs involving millions of Americans across different age groups.

One study reportedly reviewed medical records from 7.5 million Medicare beneficiaries over the age of 65 to examine possible health complications following COVID-19 vaccination. Researchers analyzed outcomes including heart attacks, strokes, Guillain-Barré syndrome, and other serious conditions during the weeks after vaccination. According to reporting on the withdrawn findings, researchers identified anaphylaxis as the only statistically notable concern, affecting roughly one in a million Pfizer vaccine recipients, while no broader elevated risks were observed.

Another study reportedly examined 4.2 million individuals between six months and 64 years old, tracking conditions such as myocarditis, blood clots, brain swelling, and seizure-related complications. Researchers again found that severe adverse events were rare, while concluding that the benefits of vaccination continued to outweigh the risks. HHS spokesperson Andrew Nixon defended the withdrawals by stating that the studies drew conclusions not fully supported by the underlying data and said the FDA acted to “protect the integrity” of the scientific process.

Scientists and Public Health Experts Push Back

The FDA’s actions have sparked criticism from medical experts, vaccine researchers, and former public health officials who argue that withholding data could undermine confidence rather than strengthen it.

Several infectious disease specialists told media outlets that peer-reviewed studies are normally challenged through scientific debate and publication responses, not by preventing the research from being released entirely. Critics say the blocked studies followed established research methods commonly used in vaccine surveillance and that transparency is essential in maintaining public trust, especially after years of political division surrounding COVID-19 vaccines.

Some experts also expressed concern that the decision reflects broader shifts inside federal health agencies under Health and Human Services Secretary Robert F. Kennedy Jr., who has long questioned vaccine safety policies. Since taking office, Kennedy has overseen cuts to vaccine-related research funding, changes to federal vaccine advisory committees, and efforts to revise immunization recommendations. Supporters of the administration argue that stricter scrutiny of vaccine studies is necessary to maintain scientific rigor, while opponents warn that suppressing favorable findings risks fueling misinformation and distrust.

Transparency, Trust, and the Future of Vaccine Policy

The dispute over these studies comes at a time when public confidence in health institutions remains fragile and vaccine skepticism continues to shape political and medical debates across the United States.

Public health experts say transparency is especially important because COVID-19 vaccines remain among the most heavily studied vaccines in modern history, with extensive clinical trials and real-world monitoring programs involving millions of people worldwide. They argue that making both positive and negative findings publicly available allows physicians, researchers, and patients to evaluate evidence independently and helps maintain credibility within the scientific process.

Whether the FDA ultimately reverses course and allows the studies to move forward remains unclear. For now, the controversy has intensified broader questions about how federal health agencies balance scientific caution, political pressure, and public communication. As debates over vaccine policy continue, the handling of these studies may become another defining test of how much trust Americans place in the institutions responsible for public health guidance.